How to buy Catalyst Pharmaceuticals (CPRX) shares in Australia

Learn how to easily invest in Catalyst Pharmaceuticals shares.

Catalyst Pharmaceuticals Inc
NASDAQ: CPRX - USD
BIOTECHNOLOGY
$5.76
- $0.17 ( - 2.87%)

We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!

Catalyst Pharmaceuticals Inc is a biotechnology business with stocks listed in the US. Catalyst Pharmaceuticals shares (CPRX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was US$5.76 – a decrease of 4.48% over the previous week. Here's how to invest if you're based in Australia.

How to buy shares in Catalyst Pharmaceuticals

  1. Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Catalyst Pharmaceuticals. Find the share by name or ticker symbol: CPRX. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Catalyst Pharmaceuticals reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of US$5.35, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Catalyst Pharmaceuticals, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Catalyst Pharmaceuticals. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Catalyst Pharmaceuticals stock price (NASDAQ:CPRX)

Use our graph to track the performance of CPRX stocks over time.

Catalyst Pharmaceuticals shares at a glance

Information last updated 2021-10-23.
52-week rangeUS$2.875 - US$6.6
50-day moving average US$5.4691
200-day moving average US$5.4002
Target priceUS$8.5
PE ratio 8.1818
Dividend yield N/A (0%)
Earnings per share (TTM) US$0.704

Where to buy Catalyst Pharmaceuticals stock

Name Product Standard brokerage for US shares Currency conversion fee Markets
eToro (global stocks)
US$0
50 pips (US$0.50 for every AU$100 exchanged)
Global shares, US shares, ETFs
Zero brokerage share trading on US, Hong Kong and European stocks with trades as low as $50.
Note: This broker offers CFDs which are volatile investment products and most clients lose money trading CFDs with this provider.
Join the world’s biggest social trading network when you trade stocks, commodities and currencies from the one account.
IG Share Trading
US$0
0.70%
ASX shares, Global shares
$0 brokerage for US and global shares plus get an active trader discount of $5 commission on Australian shares.
Enjoy some of the lowest brokerage fees on the market when trading Australian shares, international shares, plus get access to 24-hour customer support.
Superhero share trading
US$0
50 pips (US$0.50 for every AU$100 exchanged)
ASX shares, US shares
Australia’s lowest-cost broker for ASX shares and ETFs.
Pay zero brokerage on US stocks and all ETFs and just $5 (flat fee) to trade Australian shares from your mobile or desktop.
SelfWealth (Basic account)
US$9.5
0.60%
ASX shares, US shares
Trade ASX and US shares for a flat fee of $9.50, regardless of the trade size.
New customers receive free access to Community Insights with SelfWealth Premium for the first 90 days. Follow other investors and benchmark your portfolio performance.
Saxo Capital Markets (Classic account)
US$4
1%
ASX shares, Global shares, Forex, CFDs, Margin trading, Options trading, ETFs
Access 19,000+ stocks on 40+ exchanges worldwide
Low fees for Australian and global share trading, no inactivity fees, low currency conversion fee and optimised for mobile.
CMC Markets Invest
US$0
0.60%
ASX shares, Global shares, mFunds, ETFs
$0 brokerage on global shares including US, UK and Japan markets.
Trade up to 9,000 products, including shares, ETFs and managed funds, plus access up to 15 major global and Australian stock exchanges.
loading

Compare up to 4 providers

The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.

Is it a good time to buy Catalyst Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Catalyst Pharmaceuticals share growth calculator

US$

Use the fields above to explore the returns from a historical investment. Please refer to the charts further up this page to see performance over 5 years, or other periods. Past performance doesn't indicate future results. Capital is at risk.

Considering buying Catalyst Pharmaceuticals shares?

Before you consider Catalyst Pharmaceuticals, you'll want to hear this.
Ticker Nerd uses advanced software to track hundreds of signals and data points to find stocks before they blow up. You can get the next two hot stocks they find sent to your inbox for free.

Show me how

Catalyst Pharmaceuticals price performance over time

Historical closes compared with the last close of $5.76

1 week (2021-10-14) -5.26%
1 month (2021-09-24) 13.39%
3 months (2021-07-23) 3.78%
6 months (2021-04-23) 23.34%
1 year (2020-10-23) 80.56%
2 years (2019-10-24) 6.27%
3 years (2018-10-24) 85.21%
5 years (2016-10-24) 376.03%

Stocks similar to Catalyst Pharmaceuticals

Is Catalyst Pharmaceuticals under- or over-valued?

Valuing Catalyst Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Catalyst Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Catalyst Pharmaceuticals's P/E ratio

Catalyst Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 8x. In other words, Catalyst Pharmaceuticals shares trade at around 8x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Catalyst Pharmaceuticals's EBITDA

Catalyst Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$46.1 million (£0.0 million).

The EBITDA is a measure of a Catalyst Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.

Catalyst Pharmaceuticals financials

Revenue TTM US$126.9 million
Operating margin TTM 36.22%
Gross profit TTM US$87.1 million
Return on assets TTM 16.87%
Return on equity TTM 49.72%
Profit margin 58.8%
Book value 1.832
Market capitalisation US$593.2 million

TTM: trailing 12 months

Shorting Catalyst Pharmaceuticals shares

There are currently 4.7 million Catalyst Pharmaceuticals shares held short by investors – that's known as Catalyst Pharmaceuticals's "short interest". This figure is 9.2% down from 5.2 million last month.

There are a few different ways that this level of interest in shorting Catalyst Pharmaceuticals shares can be evaluated.

Catalyst Pharmaceuticals's "short interest ratio" (SIR)

Catalyst Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Catalyst Pharmaceuticals shares currently shorted divided by the average quantity of Catalyst Pharmaceuticals shares traded daily (recently around 884897.01492537). Catalyst Pharmaceuticals's SIR currently stands at 5.36. In other words for every 100,000 Catalyst Pharmaceuticals shares traded daily on the market, roughly 5360 shares are currently held short.

However Catalyst Pharmaceuticals's short interest can also be evaluated against the total number of Catalyst Pharmaceuticals shares, or, against the total number of tradable Catalyst Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Catalyst Pharmaceuticals's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Catalyst Pharmaceuticals shares in existence, roughly 50 shares are currently held short) or 0.0496% of the tradable shares (for every 100,000 tradable Catalyst Pharmaceuticals shares, roughly 50 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Catalyst Pharmaceuticals.

Find out more about how you can short Catalyst Pharmaceuticals stock.

Catalyst Pharmaceuticals share dividends

We're not expecting Catalyst Pharmaceuticals to pay a dividend over the next 12 months.

Catalyst Pharmaceuticals share price volatility

Over the last 12 months, Catalyst Pharmaceuticals's shares have ranged in value from as little as US$2.875 up to US$6.6. A popular way to gauge a stock's volatility is its "beta".

CPRX.US volatility(beta: 1.35)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Catalyst Pharmaceuticals's is 1.3466. This would suggest that Catalyst Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Catalyst Pharmaceuticals overview

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS) and myasthenia gravis; and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of anti-MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com.au:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com.au is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder only provides general advice and factual information, so consider your own circumstances, or seek advice before you decide to act on our content. By submitting a question, you're accepting our Terms of Use, Disclaimer & Privacy Policy and Privacy & Cookies Policy.
Go to site